Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
gptkb:Thomas_Oxley
|
| gptkbp:focusesOn |
medical devices
brain-computer interfaces |
| gptkbp:foundedYear |
2016
|
| gptkbp:founder |
gptkb:Thomas_Oxley
|
| gptkbp:fundedBy |
gptkb:Khosla_Ventures
gptkb:ARCH_Venture_Partners gptkb:Gates_Frontier gptkb:Neurotechnology_Investors |
| gptkbp:headquartersLocation |
gptkb:Brooklyn,_New_York,_United_States
gptkb:Melbourne,_Australia |
| https://www.w3.org/2000/01/rdf-schema#label |
Synchron
|
| gptkbp:industry |
neurotechnology
|
| gptkbp:notableAchievement |
first company to receive FDA approval for clinical trials of a brain-computer interface device
|
| gptkbp:notableEmployee |
gptkb:Thomas_Oxley
|
| gptkbp:notableProduct |
gptkb:Stentrode
|
| gptkbp:operatesIn |
gptkb:Australia
gptkb:United_States |
| gptkbp:product |
gptkb:Stentrode
|
| gptkbp:website |
https://www.synchron.com/
|
| gptkbp:bfsParent |
gptkb:Neuralink
|
| gptkbp:bfsLayer |
5
|